Adverse events among people on delamanid for rifampicin-resistant tuberculosis in a high HIV prevalence setting

Patients with rifampicin-resistant tuberculosis (RR-TB) in the township of Khayelitsha, South Africa, were offered delamanid (DLM) within a decentralised RR-TB treatment programme. To describe adverse events (AEs) among HIV-positive and negative people receiving DLM for RR-TB in a programmatic setti...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:The international journal of tuberculosis and lung disease Ročník 23; číslo 9; s. 1017
Hlavní autoři: Hughes, J, Reuter, A, Chabalala, B, Isaakidis, P, Cox, H, Mohr, E
Médium: Journal Article
Jazyk:angličtina
Vydáno: France 01.09.2019
Témata:
Adolescent
Adult
Antitubercular Agents - administration & dosage
Female
Follow-Up Studies
HIV Infections - epidemiology
Humans
Male
Nitroimidazoles - administration & dosage
Nitroimidazoles - adverse effects
Oxazoles - administration & dosage
Oxazoles - adverse effects
Prevalence
Rifampin - administration & dosage
South Africa
Tuberculosis, Multidrug-Resistant - drug therapy
Young Adult
South Africa
ISSN:1815-7920, 1815-7920
On-line přístup:Zjistit podrobnosti o přístupu
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
Popis
Shrnutí:Patients with rifampicin-resistant tuberculosis (RR-TB) in the township of Khayelitsha, South Africa, were offered delamanid (DLM) within a decentralised RR-TB treatment programme. To describe adverse events (AEs) among HIV-positive and negative people receiving DLM for RR-TB in a programmatic setting. Patients were followed up monthly for blood, electrocardiography and clinical monitoring and AEs were assessed for severity grade, seriousness and relationship to DLM. Fifty-eight patients (55% male; median age 35 years, interquartile range [IQR] 28-42) started DLM; 46 (79%) were HIV-positive, median CD4 count 173 cells/mm³ (IQR 70-294). Fifty (86%) patients experienced ≥1 new or worsening AE after starting DLM, most commonly vomiting, QTcB >450 ms and/or myalgia. Serious and/or severe AEs were experienced by 22 (38%) patients; three HIV-positive patients died (not related to DLM). HIV status was not significantly associated with number ( 0.089) or severity/seriousness ( 0.11) of AEs during exposure to DLM. Two (3%) patients had DLM withdrawn due to AEs. AEs during RR-TB treatment, both before and during DLM exposure, were common, with relatively few serious/severe AEs considered related to DLM and no significant association with HIV status. Clinical and electrocardiography monitoring should be prioritised in the first two months after starting DLM.
Bibliografie:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1815-7920
1815-7920
DOI:10.5588/ijtld.18.0651